SGLT-2 Inhibitor Dapagliflozin Gets Another Chance At FDA
This article was originally published in The Pink Sheet Daily
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will consider a new submission for AstraZeneca/Bristol-Myers Squibb’s dapagliflozin on Dec. 12. Filing includes several new studies and more long-term data.
You may also be interested in...
As well as new therapies for hepatitis C, HIV/AIDS and tuberculosis, the EU's CHMP issued a positive opinion on new active substance status for Biogen Idec's oral MS therapy dimethyl fumurate after the panel’s latest meeting.
J&J is the first pharma company to bring an SGLT2 inhibitor to market, but its window of exclusivity in that class may be narrow, given that FDA is slated to assess two other SGLT2s later this year.
FDA’s rejection of Bristol-Myers Squibb and AstraZeneca’s diabetes drug dapagliflozin may mean new trials are needed, which would be a blow for the drug as well as a bad sign for the new class of SGLT2 inhibitors.